NCT00123890
Terminated
Phase 3
A Screening Protocol to Determine Eligibility for One of Three Phase III Treatment Studies Evaluating the Efficacy and Safety of GW873140 in R5-tropic and R5/X4-tropic HIV-1 Infected, Treatment-experienced Subjects With Drug-resistant Virus or an Observational Study.
ConditionsHIV Infection
DrugsGW873140
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- HIV Infection
- Sponsor
- GlaxoSmithKline
- Locations
- 1
- Primary Endpoint
- Determination of subject eligibility for CCR102709, CCR104456, CCR104458, or CCR104629.
- Status
- Terminated
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to determine eligibility for one of three treatment studies of the CCR5 antagonist GW873140 or an observational study without GW873140. No investigational treatment will be administered through this study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •HIV-infected.
- •Screening viral load at least 5000copies/mL.
- •Total prior antiretroviral experience of at least 3 months and documented resistance to at least one drug in each of the following classes: nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI), stable antiretroviral regimen (or no antiretroviral treatment) for at least 4 weeks before screening.
- •Able to receive a ritonavir-boosted protease inhibitor during treatment studies.
- •Women of childbearing potential must use specific forms of contraception.
- •Exclusion criteria:
- •Acute laboratory abnormalities.
- •History of pancreatitis or hepatitis, hepatitis B or hepatitis C coinfection, or any chronic liver disease. Screening liver function tests will be used to determine eligibility.
- •Changes to antiretroviral therapy from 4 weeks prior to screening until Day 1 of treatment or observational studies.
- •Pregnancy or breastfeeding women.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Determination of subject eligibility for CCR102709, CCR104456, CCR104458, or CCR104629.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Eligibility Screening for National Institute of Dental and Craniofacial Research StudiesFibromyalgiaNCT00001983National Institute of Dental and Craniofacial Research (NIDCR)300
Completed
Not Applicable
Pompe Gene Therapy- Screening for EligibilityPompe Disease (Late-onset)NCT03285126Duke University19
Completed
Not Applicable
Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial HypercholesterolemiaHypercholesterolemia, FamilialNCT03018678University of Pennsylvania21
Completed
Not Applicable
A Screening Study Targeting Tumor-specific AntigensMetastatic Colorectal CancerStage II/III Colon CancerNCT05158621Gritstone bio, Inc.22
Completed
Not Applicable
Potential Research Participants for Future Studies of Inherited Eye DiseasesCataractGlaucomaRetinitis PigmentosaMacular DegenerationStrabismusNCT00559234National Eye Institute (NEI)400